Hepatic Cirrhosis Market: Epidemiology, Therapies, and Companies Working in the Space | Galectin Therapeutics, Pharmicell, Madrigal Pharmceuticals, Cymabay Therapeutics

United States, Nevada, Las Vegas, DelveInsight has launched a new report on "Hepatic Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2032".
DelveInsight's "Hepatic Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology as well as the Hepatic Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Download report @ https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the hepatic cirrhosis market:
In June 2023, Grifols Therapeutics LLC launched a Phase 3 clinical trial for Albutein 20% Injectable Solution. This open-label, randomized, controlled, parallel-group study is conducted across multiple medical centers. The primary goal is to evaluate the efficacy of combining Albutein 20% with standard medical treatment (SMT) versus SMT alone in patients with decompensated cirrhosis and ascites.
Also in June 2023, AstraZeneca initiated a Phase 2 clinical trial investigating zibotentan (dose B) in combination with dapagliflozin, as well as a placebo group (matching zibotentan capsules and dapagliflozin tablets). This study, comprising Phase IIa and IIb, is a randomized, double-blind, placebo-controlled trial conducted in parallel groups at multiple centers. Its primary aim is to assess the effectiveness, safety, and tolerability of the zibotentan-dapagliflozin combination and dapagliflozin monotherapy compared to a placebo, focusing on participants with cirrhosis and signs of portal hypertension.
Some of the key facts of the Hepatic Cirrhosis Market Report:
In 2017, cirrhosis caused more than 1.32 million 95% UI 1.27-1.45) deaths (440,000 [416,000-518,000; 33.3%] in females and 883,000 [838 000-967 000; 66.7%] in males) globally, compared with less than 899,000 (829,000-948,000) deaths in 1990. Deaths due to cirrhosis constituted 2.4% (2.3-2.6) of total deaths globally in 2017 compared with 1.9% (1.8-2.0) in 1990. Despite an increase in the number of deaths, the age-standardized death rate decreased from 21.0 (19.2-22.3) per 100,000 population in 1990 to 16.5 (15.8-18.1) per 100,000 population in 2017.
Recently in a large secondary care hospital, Hsiang et al, showed that the common primary aetiologies for liver cirrhosis were chronic hepatitis B cirrhosis (37.3%), alcoholic liver disease cirrhosis (24.1%), chronic hepatitis C cirrhosis (22.3%), and non-alcoholic fatty liver disease cirrhosis (16.4%).
According to Vaz et al the age-standardized incidence was estimated at 23.2 per 100,000 person-years (95% CI 21.3-25.1), 30.5 (95% CI 27.5-33.8) for men, and 16.4 (95% CI 14.3-18.7) for women. When stratified by age, the highest incidence rates were registered at age 60-69 years. Men had a higher incidence rate for most age groups when compared to women.
The Hepatic Cirrhosis market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
The leading Hepatic Cirrhosis Companies working in the market include NGM Biopharmaceuticals Inc, Conatus Pharmaceuticals Inc, Grifols Therapeutics LLC, Norgine, Mallinckrodt, Intercept Pharmaceuticals, and others
Key benefits of the report:
• Hepatic Cirrhosis market report covers a descriptive overview and comprehensive insight of the Hepatic Cirrhosis Epidemiology and Hepatic Cirrhosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• The Hepatic Cirrhosis market report provides insights on the current and emerging therapies.
• Hepatic Cirrhosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
• The Hepatic Cirrhosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatic Cirrhosis market.
Got queries? Click here to know more about the Hepatic Cirrhosis Market Landscape @ https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatic Cirrhosis Overview
Hepatic cirrhosis is a late-stage liver disease characterized by the replacement of healthy liver tissue with scar tissue, leading to permanent liver damage. This condition arises from various liver diseases and conditions that cause cell injury, inflammation, and eventual scarring due to the repair process. As scar tissue accumulates, it obstructs blood flow through the liver, impeding its ability to process nutrients, hormones, drugs, and natural toxins. Additionally, it diminishes the liver's production of essential proteins and other substances. Ultimately, cirrhosis impairs liver function, and late-stage cirrhosis can be life-threatening.

In developed countries, the primary causes of cirrhosis include hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). In developing regions, hepatitis B virus (HBV) and HCV are more prevalent causes. Other factors contributing to cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver damage, and chronic right-sided heart failure.

Cirrhosis is classified based on symptom presentation: decompensated cirrhosis is marked by noticeable symptoms such as jaundice, ascites (fluid accumulation in the abdomen), and hepatic encephalopathy (confusion and coma), while compensated cirrhosis does not produce these symptoms.

Complications of cirrhosis arise due to impaired liver function and disrupted blood flow. Major complications include esophageal varices and variceal hemorrhage, ascites, infections in the abdominal cavity, hepatic encephalopathy, hepatorenal syndrome, and various lung and heart issues.
Know more in detail about hepatic cirrhosis market @ https://www.delveinsight.com/sample-request/hepatic-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatic Cirrhosis Market
The Hepatic Cirrhosis market is expected to undergo significant changes in the coming years due to the anticipated introduction of new therapies from companies such as Galectin Therapeutics, Pharmicell, Madrigal Pharmaceuticals, CymaBay Therapeutics, and Galmed Pharmaceuticals, among others, throughout the forecast period from 2019 to 2032.
Hepatic Cirrhosis Treatment Market
The hepatic cirrhosis treatment market is experiencing robust growth, driven by the rising incidence of liver diseases and a growing demand for effective therapies. Hepatic cirrhosis, marked by progressive liver scarring that can lead to liver failure if untreated, is a serious condition. The market expansion is fueled by advancements in treatment options, including liver transplantation, pharmacological therapies, and minimally invasive procedures. DelveInsight's Hepatic Cirrhosis market report offers a comprehensive analysis of the condition, detailing aspects such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment strategies.
To know how the hepatic cirrhosis market is growing in the upcoming years, visit:: https://www.delveinsight.com/sample-request/hepatic-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hepatic Cirrhosis Pipeline Therapies and Key Companies
• Belapectin: Galectin Therapeutics
• Cellgram_LC: Pharmicell
• MGL-3196: Madrigal Pharmceuticals
• Seladelpar: Cymabay Therapeutics
• Aramchol: Galmed Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hepatic Cirrhosis Patient Share (%) Overview at a Glance
5. Hepatic Cirrhosis Market Overview at a Glance
6. Hepatic Cirrhosis Disease Background and Overview
7. Hepatic Cirrhosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatic Cirrhosis
9. Hepatic Cirrhosis Current Treatment and Medical Practices
10. Unmet Needs
11. Hepatic Cirrhosis Emerging Therapies
12. Hepatic Cirrhosis Market Outlook
13. Country-Wise Hepatic Cirrhosis Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hepatic Cirrhosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Download our sample report @ https://www.delveinsight.com/sample-request/hepatic-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Media Contact
Kritika Rehani
krehani@delveinsight.com
+14699457679

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.